Avid Bioservices, Inc. (CDMO)

Market Cap	1.01B
Revenue (ttm)	134.18M
Net Income (ttm)	118.25M
Shares Out	62.31M
EPS (ttm)	1.69
PE Ratio	9.58
Forward PE	81.30
Dividend	n/a
Ex-Dividend Date	n/a

Volume	451,486
Open	16.31
Previous Close	16.62
Day's Range	16.09 - 17.09
52-Week Range	11.30 - 22.83
Beta	1.85
Analysts	Buy
Price Target	22.78 (+40.7%)
Earnings Date	Mar 6, 2023

About CDMO

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides var...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1981
• Employees: 321
• Stock Exchange: NASDAQ
• Ticker Symbol: CDMO

Financial Performance

In 2022, CDMO's revenue was $119.60 million, an increase of 24.75% compared to the previous year's $95.87 million. Earnings were $127.67 million, an increase of 3747.86%.

Analyst Forecast

According to 10 analysts, the average rating for CDMO stock is "Buy." The 12-month stock price forecast is $22.78, which is an increase of 40.70% from the latest price.

Price Target

$22.78

(40.70% upside)

Analyst Consensus: Buy